Skip to main content
-

Our science

More than a 100-year experience with drug development and discovery

More than 700 scientists and specialists work within research and development in LEO Pharma to develop new treatments. Together, we take the drugs all the way - from research to registration.
Research and Development
We have more than a 100-year of experience with drug development and discovery
Our innovation ecosystem
We are committed to making great solutions through innovation
Clinical trial disclosure
We are transparent about our clinical trials' results
From idea to registration
Our continuous growth depends on the achievements of our Research and Development
PIPELINE

On our way towards the most innovative pipeline

We offer important standard treatments, as well as new innovative solutions for skin diseases. We have built one of the strongest pipelines in eczema and continue to strengthen our established portfolio
View Our Pipeline
NEWS ARTICLE

LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma

Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 M EUR has been completed.
Read the full story
NEWS ARTICLE

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825

BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
Read the full story